Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cetuximab With or Without OSI-906, a Dual Insulin-like Growth Factor-1 Receptor and an Insulin Receptor Inhibitor, in Platinum-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT01427205 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01427205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01427205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cetuximab With or Without OSI-906, a Dual Insulin-like Growth Factor-1 Receptor and an Insulin Receptor Inhibitor, in Platinum-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2013
Completion date
Not reported
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer